Advanz Pharma issued the following announcement on Nov. 30.
Concordia International Corp. ("Concordia" or "the Company") (TSX: CXR), today announced that shareholders voted in favour of a special resolution authorizing the Company to amend its articles to change its name from Concordia International Corp. to ADVANZ PHARMA Corp. Approximately 99.9 per cent of the votes cast were in favour of the special resolution.
It is expected that the limited voting shares of the Company will begin trading under the new name, and that the Company's stock symbol will change from CXR to ADVZ, on or about December 3, 2018.
"This is an exciting period for ADVANZ PHARMA, our stakeholders, and all our employees across the globe," said Graeme Duncan, the Company's Chief Executive Officer. "This new corporate identity, and the accompanying rebranding that we are working on, will help define ADVANZ PHARMA as a global pharmaceutical company that is determined to help innovate, shape and grow the specialty, off-patent sector. We will aim to go beyond what we have achieved in the past, and current industry standards, as we look to capitalize on this new start."
ADVANZ PHARMA represents a refocussed and redefined direction that will build on the Company's current capabilities, and global footprint across more than 90 countries, so that it can meet the increasingly complex needs of global healthcare systems.
Original source can be found here.